IRVINE, Calif. -- (Business Wire)
Khang & Khang LLP (the “Firm”) announces a class action lawsuit has been
filed against Seres Therapeutics (“Seres” or the “Company”) (Nasdaq:
MCRB). Investors who purchased or otherwise acquired shares between June
25, 2015 and July 29, 2016 inclusive (the “Class Period”), are
encouraged to contact the Firm prior to the November 28, 2016 lead
plaintiff motion deadline.
If you purchased shares of Seres during the Class Period, please contact
Joon M. Khang, Esquire, of Khang & Khang LLP, 18101 Von Karman Avenue,
3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail
at joon@khanglaw.com.
There has been no class certification in this case. Until certification
occurs, you are not represented by an attorney. You may choose to take
no action and remain a passive class member.
The complaint alleges that during the Class Period, Seres made
materially false and misleading statements and/or failed to disclose
material facts about its lead drug product candidate SER-109, praising
its potential and efficacy. On July 29, 2016, the Company announced that
the Phase 2 clinical trial of SER-109 did not meet its primary endpoint.
When this information was released to the public, shares of Seres
dropped in value, which caused investors harm.
If you wish to learn more about this lawsuit, or if you have questions
regarding this notice or your rights, please contact Joon M. Khang, a
prominent litigator for almost two decades, by telephone: (949)
419-3834, or via e-mail at joon@khanglaw.com.
This press release may constitute Attorney Advertising in some
jurisdictions.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160930006017/en/
Contacts:
Khang & Khang LLP
Joon M. Khang, Esq.
Telephone:
949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com
Source: Khang & Khang LLP
© 2024 Canjex Publishing Ltd. All rights reserved.